Network Bio’s Duke University deal targets a critical gap in medical AI: What happened to patients?
Network Bio partners with Duke University to link biospecimens and clinical outcomes for AI research. See the scientific and commercial implications.
Medical Devices & Diagnostics
Pharma & Biotech
Dyno Therapeutics reports 152-fold brain transduction improvement and new immune-evasive AAV capsid data at ESGCT 2026
Dyno Therapeutics reports 152-fold higher brain transduction than AAV9 in primates, plus new muscle and antibody-evasive capsid data.
Medical Devices & Diagnostics
Johnson & Johnson advances surgical AI network with Abu Dhabi and Polyphonic platform
Johnson & Johnson advances Polyphonic surgical AI deployment in Abu Dhabi. Clinical validation, data governance and hospital adoption will shape its impact.
Medical Devices & Diagnostics
A new generation of CT can sort X-ray photons by energy. GE HealthCare is taking it global
GE HealthCare’s Photonova Spectra has secured CE Mark after earlier U.S. FDA clearance and Japanese approval, accelerating the global expansion of photon-counting CT technology that promises higher-resolution and spectral imaging from individual X-ray photons.
Pharma & Biotech
Can AI simulate a human cell before the wet lab? GenBio AI says its world model brings the idea closer
GenBio AI has unveiled a virtual cell world model spanning biological scales. See what it can simulate and what still needs validation.
Medical Devices & Diagnostics
What Sentante’s physical AI strategy means for remote endovascular surgery in Europe
Sentante is using its CE-marked endovascular robot to capture force, motion and imaging data, but its clinical AI value still needs proof.
Medical Devices & Diagnostics
HOPPR’s chest CT model tackles radiology’s hardest AI test, but validation will decide what comes next
HOPPR adds a chest CT narrative model, widening developer access while leaving validation, regulation and workflow adoption as the key tests.
Pharma & Biotech
Lilly and NVIDIA commit $1bn to AI co-innovation lab for next-gen drug discovery
Eli Lilly and Company and NVIDIA have announced the formation of a co-innovation lab aimed at accelerating drug discovery using AI, robotics, and advanced compute. With a planned $1 billion investment over five years, the lab will leverage NVIDIA’s BioNeMo platform and Vera Rubin architecture alongside Lilly’s drug development expertise. The initiative represents one of